Celsion to Host Research and Development (R&D) Day on Thursday, October 12, 2017
The presentations will focus on the Company's research and development programs and will feature leading experts in directed chemotherapies and immunotherapies.
ThermoDox® - Pivotal Phase III OPTIMA Study for Primary Liver Cancer. Lead OPTIMA Study clinical investigators representing various geographical regions (
Won Young Tak, M.D., Ph.D., Professor Internal Medicine, GI & Hepatology Kyungpook National University Hospital Daegu, Republic of Korea Stephen N. Wong, M.D., Principle Investigator OPTIMA, Chinese General Hospital, Philippines Robert M. Eisele, M.D., Deputy Head of Department, Dept. of General, Visceral, Vascular and Pediatric Surgery, Medical Faculty of the University of Saarland, Homburg, Germany
GEN-1 Immunotherapy - A Powerful, Pro-Immune Modulator of Cancer's Microenvironment. The lead investigator for the Company's recently completed OVATION Study in newly diagnosed Stage III/IV ovarian cancer patients will review all of the clinical data from the trial and a leading immuno-oncology expert from
Premal H. Thaker, M.D., Associate Professor in Gynecologic Oncology, Washington University School of Medicine, St. Louis, Missouri Richard C. Koya, MD, PhD, Associate Professor of Oncology and Immunology, Director of the Vector Development & Production Facility, Associate Director of the Center for Immunotherapy, Roswell Park Cancer Institute, Center for Immunotherapy, Buffalo, NY
To ensure a timely connection, users should register at least 15 minutes prior to the scheduled start. The webcast will be archived for replay following the event for 90 days.
About the OPTIMA Study
The Phase III OPTIMA Study is expected to enroll up to 550 patients in up to 70 clinical sites in
About the OVATION Study
The Phase Ib trial was designed to evaluate weekly intraperitoneal dosing of GEN-1 in combination with neoadjuvant chemotherapy, the standard of care for patients newly diagnosed with ovarian cancer. Concurrently with neoadjuvant chemotherapy, enrolled patients will receive escalating weekly doses of GEN-1, from levels beginning at 36mg/m², to 47mg/m², 61mg/m² and 79mg/m² weekly for 8 treatments in total, with interval debulking surgery to follow. The regimen will primarily be evaluated for its safety and tolerability. GEN-1, designed using
About Celsion Corporation
Celsion Investor Contact
Sr. Vice President and CFO
News Provided by Acquire Media